BioCentury

8:00 AM GMT, Dec 24, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Big antibody deals

Big antibody deals

Partners Year Potential value Description
Genmab (CSE:GEN) GlaxoSmithKline (LSE:GSK; GSK) 2006 $2,059 GSK receives global exclusive rights to co-develop and commercialize GEN's ofatumumab for cancer and autoimmune diseases. The biotech receives a DKK582M ($102M) license fee, a DKK2B ($357M) equity investment and is eligible for up to DKK9B ($1.6B) in milestones plus double-digit royalties.

Read the full 583 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.